期刊
AMYOTROPHIC LATERAL SCLEROSIS
卷 12, 期 1, 页码 1-10出版社
INFORMA HEALTHCARE
DOI: 10.3109/17482968.2010.502940
关键词
Amyotrophic lateral sclerosis; epidemiology; diagnosis; systematic review; treatment
资金
- Istituto Superiore di Sanita
- American ALS Association (ALSA)
- NIH, National Institute on Aging
- NATIONAL INSTITUTE ON AGING [ZIAAG000933] Funding Source: NIH RePORTER
Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据